Global Cord Blood Corporation
Global Cord Blood Corporation
Your view on CORBF
Overview
What the company does, where it operates, and who runs it.
About Global Cord Blood Corporation
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Ting Zheng
- Headquarters
- Bank of China Tower, Central, HK
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Ting Zheng
- Headquarters
- Bank of China Tower, Central, HK
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China.
The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.
As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018.
Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Global Cord Blood Corporation, and the rating behind it. CORBF last traded at $0.95, 1.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Global Cord Blood Corporation. Starting points for Global Cord Blood Corporation: P/E 1.5, EPS $4.12, beta -0.67 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Global Cord Blood Corporation. Global Cord Blood Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Global Cord Blood Corporation. Trailing twelve-month EPS for Global Cord Blood Corporation stands at $4.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Global Cord Blood Corporation. Global Cord Blood Corporation has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Global Cord Blood Corporation valued side by side against its closest peers. Global Cord Blood Corporation is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Global Cord Blood Corporation, and how their positions are changing. At a $127.2M market value, institutional positions materially move Global Cord Blood Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Global Cord Blood Corporation executives and directors. Shares of Global Cord Blood Corporation have traded between $0.20 and $1.75 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Global Cord Blood Corporation. Global Cord Blood Corporation is a $127.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Global Cord Blood Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Global Cord Blood Corporation. Coverage tracks Global Cord Blood Corporation within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.